99% Iloperidone hmoovyog ib lub siab -purity dibenzoisoxazole-raws li atypical antipsychotic me me-molecule crystalline raw khoom. Nws yog npaj siv ntau-theem purification txheej txheem nrog rau cyclization ntxiv thiab gradient kub recrystallization. Nws nthuav tawm cov txiaj ntsig zoo sib xws ntawm 5-hydroxytryptamine receptor antagonistic kev ua haujlwm, nrog kev hloov pauv tsawg kawg hauv vitro qauv ntawm cov hlwb hlwb thiab cortical neurons. Feem ntau psychomodulatory me me molecules ntawm kev ua lag luam tsuas yog thaiv dopamine receptors, yooj yim inducing extrapyramidal cov tshuaj tiv thaiv, nce qib prolactin, thiab lwm yam ntxiv cuam tshuam. Cov khoom no tuaj yeem sib npaug antagonize ntau receptors (D2, 5HT2A, thiab 5HT2C), ruaj khov tswj qhov tsis sib xws ntawm lub hauv paus dopamine thiab serotonin, alleviating ob qho tib si zoo thiab tsis zoo psychosomatic txawv txav, tsis ua rau lub cev muaj kev cuam tshuam nrog lub zog dopamine blockade.
🧬 Rigid heterocyclic ruaj khov molecular configuration
Lub hauv paus ntsiab lus ntawm 99% Iloperidone hmoov yog ib qho nyuaj heterocyclic qauv ntawm dibenzoxazole. Cov molecule tsis muaj chiral carbon atoms, tshem tawm cov stereoisomerism uas tuaj yeem cuam tshuam nrog kev soj ntsuam ntawm tes. Nws conjugated aromatic nplhaib qauv ua kom ruaj khov cia. Ordinary benzene nplhaib derivatives yam tsis muaj isoxazole lub nplhaib hloov kho raug kev txom nyem los ntawm polarity tsis txaus thiab yog yooj yim thiab sai degraded raws li kev sib cuag nrog intracellular oxidases, ua rau lub sij hawm siv tau tsawg heev. Nyob rau hauv sib piv, Iloperidone hmoov cia siab rau intramolecular hydrogen bonds tsim los ntawm cov pa oxygen thiab nitrogen heteroatoms nyob rau hauv lub nplhaib isoxazole los tsim ib tug taag planar conjugated conformation. Nyob rau hauv lub teeb - tiv thaiv, kaw, thiab qhuav cia tej yam kev mob ntawm 2 mus rau 8 degree, nws muaj peev xwm tswj tau nws cov molecular molecular molecular molecular molecular lub sij hawm. Txawm hais tias thaum lub sij hawm txuas ntxiv ua ke- incubation nrog cortical neurons thiab glial hlwb rau ntau tshaj kaum hnub, nws cov dej num molecular tsis qhia qhov tseem ceeb attenuation.
Lub sab hauv isoxazole tsib- koom nrog heterocycle yog thaj chaw ua haujlwm tseem ceeb rau kev khi rau hauv nruab nrab dopamine D2 receptor. Cov nitrogen thiab oxygen atoms nyob rau hauv lub nplhaib tsim hydrogen daim ntawv cog lus qhov chaw, uas muaj peev xwm embed mus rau hauv lub hydrophobic kab noj hniav ntawm cov receptor protein, tsis tu ncua thiab kev sib tw thaiv cov endogenous dopamine binding txoj kev. Yog tias cov qauv isoxazole heterocyclic raug tshem tawm, cov molecule tsis tuaj yeem ruaj khov rau D2 receptor, ua rau lub siab luv thiab tsis muaj zog xwb- tswj cov nyhuv, ua rau nws tsis haum rau ntev -lub sij hawm neural cell passage culture systems. Cov pob txha tsis zoo dibenzoisoxazole yog lub hauv paus tseem ceeb rau Iloperidone hmoov sib npaug antagonism ntawm central receptors.
Ob lub benzene nplhaib sab chains synergistically tswj cov lipid - dej muab faib piv ntawm cov molecule, thaum lub nplhaib aromatic txhim kho cov molecule li lipid solubility, ua kom yooj yim nkag mus rau hauv cov ntshav - hlwb barrier thiab phospholipid txheej ntawm neuronal cell daim nyias nyias mus txog qhov chaw ceev ceev. Cov pab pawg alkylamine nyob rau sab chains muab hydrophilic polarity, kom ntseeg tau tias muaj kev sib cais ntawm cov molecule hauv cov kuab tshuaj organic thiab qis -concentration buffers, tiv thaiv kev sib sau thiab nag lossis daus thaum lub sij hawm gradient dilution npaj ntawm incubation daws. Polar siab heev, tsis yog -aromatic heterocyclic me me molecules tawm tsam hla lub hlwb cov ntaub so ntswg, thaum muaj zog hydrophobic, tsis yog -polar sab- cov khoom siv raw khoom yog nquag los nag hauv kab lis kev cai xov xwm.99% Iloperidone hmoovbalances central penetration thiab solvent dispersibility, ua rau nws haum rau siab -throughput neuron tshuaj ntsuam thiab loj -scale ib txhij cortical cell kab lis kev cai ua hauj lwm.
Cov molecule tag nrho tsis muaj qhov dav -spectrum cell-binding kev ua, tshwj xeeb yog paub txog dopamine thiab serotonin subtype receptors qhia nyob rau hauv lub hauv paus paj hlwb. Nws tsis muaj kev ruaj ntseg khi rau receptors nyob rau hauv peripheral somatic hlwb los yog visceral cov ntaub so ntswg, precisely qhov txawv nruab nrab lub hom phiaj proteins los ntawm cov pa cellular proteins thiab txo cov kev cuam tshuam los ntawm cov kev tsis sib haum xeeb nyob rau hauv lub soj ntsuam system. Arbitrarily cuam tshuam cov isoxazole nplhaib conjugated qauv ncaj qha txo cov molecule affinity rau central receptors, txo cov concentration zoo nyob rau hauv lub hlwb cov ntaub so ntswg thiab thiaj li tsis muaj zog nws cov kev cai ntawm kev puas hlwb txoj kev.
⚙️ Lub hauv paus ntsiab lus ntawm kev sib npaug antagonistic nyhuv ntawm ntau tus receptors
Nyob rau hauv lub cev noj qab haus huv, qhov tso tawm ntawm dopamine thiab serotonin neurotransmitters nyob rau hauv lub hauv paus paj hlwb tswj lub dynamic tshuav nyiaj li cas. Cov qib kev sib txuas ntawm D2 thiab 5HT2A receptors yog nruab nrab, ua kom muaj kev ua haujlwm zoo thoob plaws hauv cov txheej txheem kev paub, kev xav paub, thiab kev tswj xyuas lub cev muaj zog. Microglia tso tawm pro- cov teeb meem inflammatory nrog kev ua haujlwm tsawg, neuronal synaptic plasticity tseem zoo, thiab intracellular ion metabolism thiab cov txheej txheem txhais cov protein tsis cuam tshuam los ntawm exogenous me me molecules. Neuronal proliferation thiab kev sib txawv ua kom zoo li homeostasis.
Thaum lub hauv paus neurotransmitter secretion tsis zoo, ntau dhau dopamine tso tawm tsis tu ncua ua rau D2 receptors, thaum 5HT2A thiab 5HT2C receptor signaling dhau los ua qhov tsis txaus ntseeg, ua rau muaj ntau yam txawv txav xws li kev nkag siab txawv txav, kev xav tsis meej pem, thiab kev xav tsis zoo. Ntev -lub sij hawm neurotransmitter tsis sib npaug kuj txhawb nqa glial hlwb kom tso tawm ntau cov pro- cov kab mob inflammatory, ua rau cov kab mob prefrontal cortex. Cov paib ib leeg -dopamine blockade tsuas yog txwv tsis pub D2 txoj hauv kev, cuam tshuam serotonin tshuav nyiaj li cas thiab ua rau muaj kev cuam tshuam thib ob xws li ceg tawv thiab cov kab mob endocrine, tsis ua kom tag nrho hauv nruab nrab neurotransmitter homeostasis.
Tom qab nkag mus rau cov ntshav- lub hlwb thaiv thiab mus txog thaj tsam prefrontal thiab striatal neural,99% Iloperidone hmoov, cia siab rau dibenzoxazole conjugate scaffold, thawj zaug sib tw khi rau dopamine D2 receptors, thaiv qhov kev ua kom tsis tu ncua ntawm cov cim dopamine ntau dhau thiab txo qhov txawv txav cuam tshuam txog kev hnov qab; thib ob, nws lub hom phiaj thiab antagonizes 5HT2A receptors, downregulating lub overactivated serotonin excitation txoj kev thiab txhim kho mus ob peb vas swings thiab pw tsaug zog cuam tshuam; Thib peb, nws me ntsis thaiv 5HT2C receptors, tswj kev sib kis ntawm neural ntsig txog qab los noj mov thiab apathy. Qhov kev tswj hwm ib txhij thiab sib npaug ntawm peb lub receptors kho lub hauv nruab nrab lub paj hlwb tsis txaus los ntawm ntau qhov chaw neurotransmitter, tsis zoo li cov khoom xyaw psychoactive uas tsuas yog thaiv dopamine receptors.
99% Iloperidone hmoov tsuas yog tswj cov kab mob neurotransmitter kev sib kho los ntawm tshwj xeeb D2 / 5HT multi- receptor txoj hauv kev hauv nruab nrab neurons, tsis cuam tshuam nrog peripheral receptors thauj cov qauv rau adrenaline, histamine, thiab lwm yam, thiab tsis cuam tshuam rau basal metabolic voj voog ntawm visceral hlwb. Dav -spectrum centrally active tshuaj indiscriminately thaiv ntau neural receptors thoob plaws hauv lub cev. Cov txheej txheem soj ntsuam yog sib xyaw nrog ntau tus endocrine thiab lub cev muaj zog- cuam tshuam tsis cuam tshuam cov teeb liab. 99% Iloperidone hmoov muaj cov txheej txheem meej thiab tshwj xeeb. Cov txheej txheem soj ntsuam cuam tshuam tuaj yeem kho qhov sib txawv ntawm "central dopamine-serotonin balance regulation" thiab txhim kho qhov tseeb ntawm kev soj ntsuam cov lus xaus ntsig txog kev puas hlwb thiab kev puas hlwb.
🧫 Me me molecule ntau- cov ntawv thov tshawb fawb txog kev tshawb fawb
99% Iloperidone hmoov yog cov txheej txheem tswj cov khoom siv rau kev soj ntsuam ntawm central neurotransmitter imbalance nyob rau hauv schizophrenia, feem ntau yog siv rau kev tsim kho ntawm thawj prefrontal cortex neurons thiab peb -dimensional hlwb organoid dopamine hyperactivity raug mob qauv. Kev tso tawm ntau dhau ntawm lub hauv paus dopamine txuas ntxiv ua rau D2 receptors, inducing perceptual abnormalities. Leveraging cov cuab yeej ntawm Iloperidone hmoov kom sib npaug thiab antagonize ntau receptors, nws yuav siv tau rau kom muaj nuj nqis fluorescence ntawm receptor binding, electrophysiological kaw ntawm neuronal firing, thiab nrhiav kom paub txog kev txawj ntse - hais txog cov protein. Qhov no tso cai rau tsim kom muaj ib qho kev ntsuam xyuas tus qauv rau cov tshuaj psychoactive, thiab hla -kev sib piv ntawm cov neurotransmitter tshuav nyiaj li cas kho lub peev xwm ntawm ntau yam hauv nruab nrab lub hom phiaj me me molecules thiab heterocyclic derivatives.
Cov khoom siv dav siv hauv kev soj ntsuam neuropharmacological ntawm kev puas siab puas ntsws bipolar thiab kev ntxhov siab ntev, thiab yog tsim rau co- kab lis kev cai qauv ntawm cortical hlwb induced los ntawm dopamine-serotonin imbalance. Ntev -lub sij hawm mus ob peb vas ib txhij yuav ua rau txawv txav hyperactivity ntawm ob txoj kev neurotransmitter.99% Iloperidone hmoovtuaj yeem sib npaug ntawm ntau lub hauv paus receptor signals, txo cov neuronal tshaj -excitation, elucidate lub compensatory qauv ntawm mus ob peb vas-txog neurotransmitters, tshuaj ntsuam rau active tshuaj uas stabilize mus ob peb vas, thiab txhim kho qhov kev tshuaj ntsuam platform rau me me molecules rau mus ob peb vas kev cai.
Nws muaj tus nqi hloov pauv tsis tau nyob rau hauv kev soj ntsuam cov txheej txheem hauv qab kev puas siab puas ntsws thib ob tom qab raug mob lub hlwb thiab kev paub tsis meej hauv cov neeg laus, thiab yog siv los tsim cov qauv hauv vitro ntawm kev puas siab puas ntsws cortical neurons thiab cov laus lub hlwb. Kev raug mob ntawm lub hlwb thiab kev laus ib txhij cuam tshuam cov kev tso tawm suab ntawm dopamine thiab serotonin, ua rau lub siab tsis tu ncua thiab kev nkag siab ntawm qhov txawv txav . 99% Iloperidone hmoov tuaj yeem sib npaug ntawm ntau yam receptors, thiab tau siv dav hauv kev tshawb nrhiav tom qab- kev tshawb fawb txog kev puas siab puas ntsws {3} thiab txo qis kev puas siab puas ntsws {3} thiab kev loj hlob ntawm me me molecules rau central tiv thaiv cov teebmeem nrog sib npaug antagonism ntawm ntau receptors.
Txoj kev loj hlob ntawm cov tshiab atypical antipsychotic lead molecules thoob ntiaj teb sib npaug siv 99% Iloperidone hmoov raws li qhov kev siv tau zoo. Ntau yam heterocyclic hloov derivatives, lub hlwb cov ntaub so ntswg - phiaj prodrugs, thiab ntev - ua centrally modulating me me molecules yuav tsum tau ntoo khaub lig-sectional sib piv ntawm core indicators xws li ntau yam receptor binding efficiency, neuronal excitation thiab inhibition amplitude, thiab peripheral {5} solubility. Qhov ruaj khov thiab sib npaug sib npaug receptor antagonistic kev ua si, tsis tshua muaj kev cuam tshuam - lub hom phiaj cuam tshuam, thiab cov ntaub ntawv tshawb xyuas cov hlwb neuronal ua rau nws yog tus qauv siv thoob ntiaj teb rau siab - dhau los ntawm kev tshuaj ntsuam, cov qauv heterocyclic- kev txheeb xyuas kev sib raug zoo, thiab rov ua kom zoo dua ntawm cov qauv molecular rau hauv nruab nrab molecules.
🔬 Kev Txhim Kho thiab Kev Txhim Kho Cov Lus Qhia ntawm Heterocyclic Molecules
Site-Kev hloov kho tshwj xeeb ntawm isoxazole nplhaib sab saw alkyl pab pawg tam sim no yog txoj hauv kev tseem ceeb rau kev ua kom zoo dua 99% ntawm iloperidone hmoov molecules, nrog rau cov chaw hloov kho tsom mus rau cov pab pawg dav hlau alkylamine. Tus thawj me me molecule diffuses uniformly thoob plaws hauv lub cev, tab sis nws enrichment concentration nyob rau hauv prefrontal thiab striatal lesions yog txwv, yuav tsum tau ib tug nruab nrab concentrations exert nws multi- receptor antagonistic nyhuv. Tom qab grafting lub paj hlwb vascular endothelium- tshwj xeeb affinity luv peptide mus rau alkylamine davhlau ya nyob twg, cov kev hloov kho derivative tuaj yeem coj mus rau hauv qhov chaw nruab nrab ntawm lub paj hlwb. Cov koob tshuaj qis qis tuaj yeem sib npaug ntawm txoj hauv kev dopamine thiab serotonin, txo qhov cuam tshuam ntawm peripheral somatic hlwb kom taug qab cov khoom me me, thiab hloov mus rau kev tsim kho ntawm qis- koob tshuaj, ntev- ua haujlwm nruab nrab neurotransmitter sib npaug qauv.
Responsive modification to the microenvironment of central neurotransmitter imbalance is another mainstream optimization route, kev txhim kho me ntsis basal cellular metabolic cuam tshuam los ntawm indiscriminate diffusion ntawm me me molecules. Los ntawm kev grafting cov esterases uas muaj zog heev mus rau isoxazole nplhaib sab saw nyob rau hauv cov hlab ntsha tsis sib haum xeeb, cov pab pawg npog tuaj yeem raug cleaved, tsim cov kab mob - tshwj xeeb activating prodrug. Cov kev hloov kho prodrug tsis muaj receptor- khi kev ua haujlwm hauv cov neurons noj qab haus huv, yog li tsis cuam tshuam nrog basal neurotransmitter metabolism. Tsuas yog thaum nkag mus rau cov paj hlwb puas nrog dopamine ntau dhau thiab serotonin tsis txaus ua lub npog ntsej muag pab pawg hydrolyze thiab tshem tawm, tso tawm cov tub ntxhais Iloperidone nquag. Qhov no yog tswj hwm ntau lub hauv paus receptors, ntxiv dag zog rau qhov tshwj xeeb ntawm cov molecular thiab ua raws cov qauv ntawm qis - toxicity, centrally targeting, thiab stabilizing me me molecules.
Multifunctional hybrid molecules nthuav dav lawv thaj tsam ua haujlwm, kov yeej cov kev txwv ntawm ib leeg -receptor antagonism. Ntev - lub sij hawm nruab nrab ntawm lub paj hlwb puas feem ntau nrog oxidative kev nyuaj siab thiab synaptic atrophy; tsuas yog ntsuas cov neurotransmitter receptors tsis tuaj yeem kho lub hlwb puas. Los ntawm covalently splicing lub Iloperidone dibenzisoxazole core moj khaum nrog synaptic regeneration thiab antioxidant active fragments, ib tug multifunctional fusion me me molecule yog tsim. Qhov no ib txhij ua tiav kev sib haum xeeb ntawm kev sib haum xeeb ntawm lub hauv paus receptors, kho cov neuronal synapses, thiab kev tshem tawm ntawm cov kab mob hauv cov cellular reactive oxygen, kov yeej qhov tsis txaus ntawm ib leeg - phiaj xwm hauv nruab nrab cov ntaub ntawv raw cov ntaub ntawv thiab muab cov kev nkag siab tshiab rau kev tsim qauv ntawm cov kab mob kev puas siab puas ntsws nyuaj.
Los ntawm kev hloov cov benzene rings ntawm ob sab, receptor binding bias tuaj yeem raug kho kom zoo kom tau raws li tus kheej xav tau ntawm qhov sib txawv hauv nruab nrab paj hlwb kev soj ntsuam scenarios. Tus thawj99% Iloperidone hmoovmuaj qhov sib npaug antagonistic lub zog tiv thaiv D2, 5HT2A, thiab 5HT2C receptors, ua rau nws haum rau cov qauv schizophrenia cell. Tom qab hloov hom benzene nplhaib hloov pauv, muaj zog dopamine - inhibiting derivatives thiab me serotonin - tswj derivatives tuaj yeem npaj tau. Lub hwj chim version yog tsim rau luv luv - lub sij hawm cuam tshuam kev soj ntsuam ntawm mob dopamine hyperactivity, thaum lub sij hawm ncua -tso tawm version yog haum rau ntev- lub sij hawm passaging kab lis kev cai qauv ntawm neurons nyob rau hauv lub mus ob peb vas tsis zoo, ua kom meej kev soj ntsuam ntawm central neurotransmitter kev cai raws li subtype.
Xaus
99% Iloperidone hmoov cia siab rau qhov sib xyaw ua ke ntawm heterocyclic ruaj khov crystalline moj khaum ntawm dibenzisoxazole. Los ntawm antagonizing ntau lub hauv paus D2, 5HT2A, thiab 5HT2C neurotransmitters, nws ib txhij tswj qhov tsis txaus ntawm dopamine thiab serotonin, thiab tsis tu ncua txhim kho kev nkag siab thiab kev xav txawv txav vim los ntawm ntau yam hauv nruab nrab neurotransmitter mob. Nws tuaj yeem siv los tsim cov qauv hauv vitro neuronal ntawm dopamine hyperactivity hauv schizophrenia, thiab tseem tuaj yeem siv los soj ntsuam cov txheej txheem ntawm kev puas siab puas ntsws bipolar thiab kev puas siab puas ntsws theem nrab tom qab raug mob hlwb. Nws nthuav peb txoj haujlwm tseem ceeb: psychopharmacology, central neurotransmitter kev tswj hwm, thiab kev kho lub siab tom qab lub hlwb raug mob.
Xi'an Faithful BioTech yog koj tus neeg muag khoom ntseeg siab ntawm99% Iloperidone hmoov. Peb muab cov kws tshuaj - cov khoom qib thiab xyuas kom peb cov txheej txheem tsim ua raws li GMP cov qauv. Peb pab neeg muaj kev paub dhau los ntawm cov kws tshaj lij tuaj yeem kho cov kev daws teeb meem rau koj ntau yam kev xav tau ntawm kev lag luam, suav nrog kev yuav khoom luv nqi, kev pab nrog cov ntaub ntawv tswj hwm, thiab hloov pauv kev txiav txim rau ntau qhov sib txawv. Thov hu rauallen@faithfulbio.comlos tham txog koj cov kev xav tau thiab kawm seb peb cov khoom zoo li cas - cov ntaub ntawv zoo tuaj yeem pab txhawb koj txoj kev loj hlob ntawm cov khoom.
Cov ntaub ntawv
- AK Kev Tshawb Fawb. (2026). Iloperidone, 99% (HPLC) [Product B599]. Tau txais Lub Xya Hli 6, 2026.
- Therapeutic Target Database. (nd). Cov ntsiab lus ntawm Active Pharmaceutical Ingredient (API): Iloperidone (ID: D00323). Tau txais Lub Xya Hli 6, 2026.
- US National Library of Medicine. (2009). Iloperidone (Fanapt) ntsiav tshuaj. Pharmaceutical Approval Update, 34(7), 383-388. NIH Pub Med Central.
- ScienceDirect. (2025). Ex vivo kev tshawb fawb nrog iloperidone (HP 873), muaj peev xwm atypical antipsychotic nrog dopamine D2 / 5-hydroxytryptamine2 receptor antagonist kev ua. Phau ntawv Journal of Pharmacology and Experimental Therapeutics. Tau txais Lub Xya Hli 6, 2026.
- SciFinder. (nd). Iloperidone (CAS 133454-47-4). Chemical Abstracts Service.
- ScienceDirect. (2012). Iloperidone (Fanapt®). Hauv Bioorganic & Medicinal Chemistry. Tau txais Lub Xya Hli 6, 2026.
- AbMole BioScience. (nd). Iloperidone (Cat. No. M1574). Tau txais Lub Xya Hli 6, 2026.